Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial
British Journal of Haematology · 2026-08 · 209 (2) · 557-568
DOI: 10.1111/bjh.70611 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Haematology, online erschienen am 16.06.2026. Verfasst von Andrew Hall und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol Myers Squibb (formerly Celegene), Myeloma UK.
Abstract (Originalsprache)
There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label phase 2 trial. The planned sample size was 250 patients but recruitment was stopped early due to changes in standard of care. Between 2016 and 2018, 104 RRMM patients from 26 UK hospitals were recruited and randomized to receive cyclophosphamide, pomalidomide, and dexamethasone (CPd) or pomalidomide and dexamethasone (Pd) using minimization. Fifty‐four participants in each arm were analysed. The primary end‐point, progression‐free survival (PFS) was not met with median 6.9 months (95% Confidence Interval (CI): 5.7–10.4) for CPd versus 4.6 months for Pd (95% CI: 3.5–7.4), although not significant; reflecting underpowering from early closure. CPd showed a higher overall response rate, and toxicity was comparable to previously reported Pd regimens. Peripheral blood T‐cell analysis revealed stronger and more sustained enrichment of CD3+ T cells, HLA‐DR‐positive CD8+ and CD8+ effector memory cells in the CPd arm. Pretreatment CD4+ T‐cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T‐cell composition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
- The Institute of Cancer Research, London, UK.
- The Royal Marsden Hospital, London, UK.
- Leicester Royal Infirmary, Leicester, UK.
- National Institute for Health and Care Research Leeds Biomedical Research Centre, Leeds, UK.
- Translational Development and Diagnostics, Celgene Corporation, Summit, New Jersey, USA.
ORCID-Profile: Andrew Hall, Mamta Garg
Förderung
- Bristol Myers Squibb (formerly Celegene)
- Myeloma UK
Zitieren
APA
Hall, A., Croft, J., Walker, K., Boyd, K., Roberts, S., Holroyd, A., Garg, M., Ferris, E., Cook, G., Pierceall, W. E., Thakurta, A., Gandhi, A., Pawlyn, C., Brown, S. R., & Kaiser, M. (2026). Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial. British Journal of Haematology, 209(2), 557-568. https://doi.org/10.1111/bjh.70611
Vancouver
Hall A, Croft J, Walker K, Boyd K, Roberts S, Holroyd A, et al. Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial. British Journal of Haematology. 2026;209(2):557-568. doi:10.1111/bjh.70611
BibTeX
@article{Hall2026,
author = {Hall, Andrew and Croft, James and Walker, Katrina and Boyd, Kevin and Roberts, Sadie and Holroyd, Amy and Garg, Mamta and Ferris, Elsa and Cook, Gordon and Pierceall, William E and Thakurta, Anjan and Gandhi, Anita and Pawlyn, Charlotte and Brown, Sarah R and Kaiser, Martin},
title = {Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {2},
pages = {557--568},
doi = {10.1111/bjh.70611}
}
EUVIMED